10 October 2022 - Supernus Pharmaceuticals today announced that the US FDA has issued a complete response letter for the SPN-830 new drug application. 

SPN-830 is an investigational apomorphine infusion device under review for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease.

Read Supernus Pharmaceuticals press release